{"disease":{"id":"biliary-dyskinesia","name":"Biliary dyskinesia","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"aclatonium","indication_name":"Biliary dyskinesia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abovis","generic_name":"ACLATONIUM","company_name":"","drug_phase":"phase_2","molecular_target":"Muscarinic acetylcholine receptor","drug_class":"aclatonium","quality_score":23,"revenue":null,"mechanism":"Abovis works by binding to the muscarinic acetylcholine receptor, a protein that plays a key role in regulating various bodily functions."},{"drug_id":"flopropione","indication_name":"Biliary dyskinesia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cospanon","generic_name":"FLOPROPIONE","company_name":"","drug_phase":"phase_2","molecular_target":"Catechol O-methyltransferase","drug_class":"","quality_score":null,"revenue":null,"mechanism":"FLOPROPIONE works by inhibiting the enzyme Catechol O-methyltransferase, which plays a role in the regulation of bile flow."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06481007","title":"ALgerian Cholecystectomy Outcomes and Determinants Study (AL-CODS)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"University of Oran 1","has_results":false},{"nct_id":"NCT06842966","title":"Efficacy, Safety, and Tolerability of 4-MUST Tablets in Chronic Cholecystitis and Biliary Dyskinesia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Valenta Pharm JSC","has_results":false},{"nct_id":"NCT07421011","title":"Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Valenta Pharm JSC","has_results":false},{"nct_id":"NCT04915651","title":"Gallbladder Cryoablation in High-Risk Patients","phase":"NA","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"University of Arizona","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}